The latest recommendations for the management of ankylosing spondylitis
More details
Hide details
Online publication date: 2006-12-15
Reumatologia 2006;44(6):330-334
Ankylosing spondylitis (AS) is a chronic inflammatory disease that leads to loss of function and disability in patients. AS is responsible for significant direct and indirect socioeconomic costs. Few studies have been performed on the treatment of patients with AS with disease-modifying antirheumatic drugs, none of which have proved clearly effective in axial disease. In the last few years the results of randomised controlled trials have raised good evidence that TNF-α blockade is very effective in AS and other spondyloarthropathies. Recently published guidelines for treatment of AS are discussed. There is a need for safety and socioeconomic data for long-term treatment with biologicals.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top